TMT Acquisition Corp Announces Adjournment of Extraordinary General Meeting
New York, New York, March 28, 2024 (GLOBE NEWSWIRE) — TMT Acquisition Corp (Nasdaq: TMTCU, TMTC, and TMTCR) (the “Company”) […]
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 […]
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline […]
Shapeways Reports Fourth Quarter and Full Year 2023 Results
– Expands Q4 2023 Gross Margins to 46% and Increases Gross Profit by 23% vs the same quarter in the […]
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim […]
NaaS Technology Inc. Reports Unaudited 2023 Fourth Quarter and Full Year Financial Results
BEIJING, March 28, 2024 (GLOBE NEWSWIRE) — NaaS Technology Inc. (“NaaS” or the “Company”) (Nasdaq: NAAS), the first U.S. listed […]
Wintrust Financial Corporation Announces First Quarter 2024 Earnings Release Schedule
ROSEMONT, Ill., March 28, 2024 (GLOBE NEWSWIRE) — Wintrust Financial Corporation (“Wintrust”) (Nasdaq: WTFC) today announced it will release first […]
IB Acquisition Corp. Announces Closing of $115,000,000 Initial Public Offering, Including Full Exercise of Underwriter Over-Allotment Option
Boca Raton, Florida, March 28, 2024 (GLOBE NEWSWIRE) — IB Acquisition Corp. (NASDAQ: IBACU) (the “Company”) announced today the closing […]
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
– Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 – – UNI-494 Granted Orphan Drug Designation in Delayed Graft […]
AGBA Announces Fourth Quarter 2023 Earnings, Amid Challenging Macro Environment.
HONG KONG, March 28, 2024 (GLOBE NEWSWIRE) — NASDAQ-listed, AGBA Group Holding Limited (“AGBA” or “the Company”) the leading one-stop […]
